((自动化翻译由路透提供，请见免责声明 ))
10月28日 - ** Monopar Therapeutics 公布股票募集计划后，盘后股价下跌约18%，至14.65美元。 ** 该公司宣布在尽力而为的基础上发行 (link) 股票；交易规模未披露
** 该公司计划将募集资金净额用于一般用途，包括研发、临床试验支出等。
** 该公司有 390 万股已发行股票，市值约为 7000 万美元，自由流通股约为 200 万股（根据伦敦证交所集团数据）。
** MNPR 周一收盘上涨 5.3%，报 17.83 美元 ** 周四，该公司与阿斯利康 签订了 (link) 许可协议，AZN 的实验性药物正在接受威尔逊病（Wilson disease (link)）的测试，这是一种罕见的遗传病，会导致有毒铜含量的积累，之后该公司股价从 4.63 美元飙升了 7 倍，收于 32.66 美元。
** 罗德曼-伦肖公司（Rodman & Renshaw）股票发行的独家配售代理
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.